login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Banned Drug Thalidomide Shows Promise for Recurrent Ovarian Treatment
In the study, led by Levi Downs, Jr., M.D., assistant professor and a researcher of gynecologic oncology at the University of Minnesota Medical School and Cancer Center, Phase II clinical trial was randomized.
For some women, ovarian cancer has become a chronic disease. The standard chemotherapy regimens can put recurrent cancer in remission, often more than once. However, when the cancer resists the standard treatments, we need new options for treatment, Downs said.
The study compared the effectiveness and safety of the combination of thalidomide and topotecan, a chemotherapy often used for ovarian cancer, versus topotecan alone for treatment of recurrent epithelial ovarian cancer in patients who had received prior treatment.
Epithelial ovarian cancer is a disease in which cancer cells form in the tissue that covers the ovary.
In the study, 75 women were evaluated who were randomly assigned to receive either the combination of thalidomide and topotecan or only topotecan.
We found that patients who received topotecan plus thalidomide showed an overall response rate of 47 percent compared to 21 percent response in patients who received only topotecan. In patients receiving topotecan plus thalidomide, 30 percent achieved a complete response, meaning the cancer went away, compared to 18 percent for patients only getting topotecan, Downs said.
|
|
|
More News on: Drug Toxicity, Signature Drug Toxicity
 Comment & Contribute
|
Medwonders Health Network
- Health News Index
- News Quick Links
 | News Central | | Health Watch | |
| Latest Health News | | Health In Focus | |
| News Category (500+) | | Breaking Health News | |
| Popular News | | Celebrating Life | |
| Health News and Press Release | | Medindia - Exclusive | |
| News Photo Gallery | | India Special | |
| News Video Gallery | | Lifestyle and Wellness | |
| News From Other Resources | |||
| News Categories: |
| » | Revision in Quality Standards for Heparin |
| » | Acne Drug Users At High Risk of Developing Eye Infections |
| » | Patients Who Take Antidepressants When in ICU More Likely to Die |
| » | New Tablet Coating Product by Ideal Cures, In Geneva |
| » | Prednisolone Benefits Patients With Bell's Palsy |
| More Drug News | |
|
Drug Related News |
||||||||
| » | Revision in Quality Standards for Heparin | » | Acne Drug Users At High Risk of Developing Eye Infections | |||||
| » | Patients Who Take Antidepressants When in ICU More Likely to Die | » | New Tablet Coating Product by Ideal Cures, In Geneva | |||||
| » | Prednisolone Benefits Patients With Bell's Palsy | » | 'Orphan' Sleep Drug may Fight Cancer | |||||
| » | New Drugs for Fox Tapeworm Infection | » | Poor Quality Antimalarial Drugs Pose Threat | |||||
| Read More >> | ||||||||
